After Stada CEO Peter Goldschmidt brushed off the possibility of a deal for some Takeda drugs in western Europe, the German generics player has laid hands on a different Takeda portfolio—and it’s the largest acquisition in the company’s history.
Takeda agreed to sell some over-the-counter and prescription drugs in Russia, Georgia and several other Commonwealth countries to Stada for $660 million, the Japanese pharma said Tuesday.
The ax is falling on about 20 assets in the region, including OTC vitamins and food supplements as well as drugs in cardiovascular, diabetes, general medicine and respiratory therapeutic areas.
Blood clot buster Cardiomagnyl (magnesium hydroxide), which Takeda acquired in its 2011 Nycomed buyout, is cited as a key growth driver within the portfolio. Patent-protected diabetes treatment Nesina and blood pressure therapy Edarbi are also included.
About 500 current Takeda employees in sales and marketing could jump to the German drugmaker when the transaction closes, which is expected in the quarter ending March 31. The Japanese pharma will continue to manufacture and supply the products to Stada.
Combine this Stada pact with Takeda’s recent deal to hive off some 30 drugs in the Middle East and Africa to Switzerland’s Acino International, and the emerging markets products Takeda is selling generated $300 million in revenues in its previous fiscal year, the company said.
“Takeda remains committed to the emerging markets, Russia and the countries included in this agreement,” Takeda’s president of the Growth & Emerging Markets Business Unit, Ricardo Marek, said in a statement. “We are confident that Stada is well placed to provide patients with uninterrupted access to the divested products—a top priority for Takeda.”
Takeda is moving one step closer to its target of cutting loose about $10 billion worth of drugs outside of its five key business areas—gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience—to help pay down the debt incurred in its $59 billion takeover of Shire.
Other than the two emerging markets deals with Acino and Stada, it has transferred Shire’s eye drug Xiidra to Novartis for up to $5.3 billion and penned a deal with Johnson & Johnson’s Ethicon over its TachoSil patch for $400 million.
For Stada, the deal marks the largest acquisition in the German company’s history, according to Goldschmidt. It enriches the German company’s existing offerings in Russia and the Commonwealth region and further expands its consumer health business.
“Stada’s branded products are already well-represented in the most popular pharmacy categories in our key markets,” he said in a statement. “However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments.”
Stada has been on an acquisition spree lately. Monday, the company said it would acquire Czech Republic-headquartered Walmark for an undisclosed amount, nabbing a “market-leading” consumer health portfolio in central Europe, along with more than 540 employees and a manufacturing facility in Trinec, Czech Republic.
The company also recently took in six OTC brands—including five skincare products and a pediatric cough remedy—from GlaxoSmithKline, which is itself looking to exit the consumer health business.
By Angus Liu
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.